Format

Send to

Choose Destination
Adv Cancer Res. 2015;126:305-44. doi: 10.1016/bs.acr.2014.11.007. Epub 2015 Feb 7.

Glycosylation alterations in lung and brain cancer.

Author information

1
Department of Surgery, Thoracic Oncology Program, University of California, San Francisco, California, USA.
2
Department of Neurological Surgery, Brain Tumor Research Center, University of California, San Francisco, California, USA.
3
Department of Neurological Surgery, Brain Tumor Research Center, University of California, San Francisco, California, USA; Department of Pathology, University of California, San Francisco, California, USA. Electronic address: Joanna.Phillips@ucsf.edu.

Abstract

Alterations in glycosylation are common in cancer and are thought to contribute to disease. Lung cancer and primary malignant brain cancer, most commonly glioblastoma, are genetically heterogeneous diseases with extremely poor prognoses. In this review, we summarize the data demonstrating that glycosylation is altered in lung and brain cancer. We then use specific examples to highlight the diverse roles of glycosylation in these two deadly diseases and illustrate shared mechanisms of oncogenesis. In addition to alterations in glycoconjugate biosynthesis, we also discuss mechanisms of postsynthetic glycan modification in cancer. We suggest that alterations in glycosylation in lung and brain cancer provide novel tumor biomarkers and therapeutic targets.

KEYWORDS:

Biomarker; GBM; Glioblastoma; Glycosylation in cancer; HPSE; HSPG; Lung cancer; SULF

PMID:
25727152
PMCID:
PMC6080207
DOI:
10.1016/bs.acr.2014.11.007
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center